Peer-review started: December 15, 2021
First decision: March 16, 2022
Revised: March 29, 2022
Accepted: April 24, 2022
Article in press: April 24, 2022
Published online: June 2, 2022
Processing time: 166 Days and 13.9 Hours
There are 422 million diabetic people in the world. 25% of these individuals are diagnosed with diabetic foot ulcer (DFU). 20% of patients with DFU will suffer amputation of the lower limbs. Following amputation procedures, the mortality rate of patients is over 70% in 5 years. Diabetes has no cure and, therefore, treatment aims to prevent and treat its complications. Autologous platelet-rich plasma (PRP) has been shown to be a therapeutic tool for many types of disorders, including the treatment of DFU. This manuscript aims to carry out a review to provide more knowledge about the efficacy and safety of autologous PRP for wound closure in patients with DFU. The majority of studies included in this review state that PRP promotes improvement of DFU lesions by accelerating tissue healing processes. However, many studies have a small sample size and thus require larger sample range in order to improve robustness of data in the literature.
Core Tip: Platelet-rich plasma (PRP) can be produced by the centrifugation of a patient's peripheral blood, separating the mixture into distinct layers containing plasma, platelets, leukocytes and erythrocytes. An elevated concentration of platelets above the basal value enables accelerated growth of bone and soft tissues with minimal side effects. Autologous PRP administration is a relatively new biotechnology undergoing expansion which continues to reveal optimistic results in the stimulation and enhanced healing of various sorts of tissue injuries.